LeonaBio (LONA) Research & Development (2019 - 2026)
LeonaBio (LONA) reported Research & Development of $11.3 million for Q1 2026, up 161.79% year-over-year from $4.3 million in Q1 2025, and up 67.79% on a QoQ basis from $6.7 million in Q4 2025.
LeonaBio (LONA) has 8 years of Research & Development data on file, last reported at $11.3 million in Q1 2026.
- Quarterly Research & Development rose 161.79% year-over-year to $11.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.5 million (down 54.49% YoY) and the FY2025 annual result came in at $17.5 million, down 75.24% from the prior year.
- Research & Development advanced to $11.3 million in Q1 2026 per LONA's latest filing, from $6.7 million in the prior quarter.
- Across five years, Research & Development topped out at $27.2 million in Q3 2023 and bottomed at $2.8 million in Q3 2025.
- The 5-year median for Research & Development is $15.2 million (2022), against an average of $15.0 million.
- The widest annual swing landed in 2025, when Research & Development sank 84.24%; it then soared 161.79% in 2026.
- Tracing LONA's Research & Development over 5 years: stood at $15.2 million in 2022, then surged by 55.42% to $23.7 million in 2023, then plunged by 60.43% to $9.4 million in 2024, then decreased by 28.37% to $6.7 million in 2025, then surged by 67.79% to $11.3 million in 2026.
- Per Business Quant, the three latest LONA Research & Development figures stand at $11.3 million (Q1 2026), $6.7 million (Q4 2025), and $2.8 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | 11.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.26 Mn |
| Dec 31, 2025 | 6.71 Mn |
| Sep 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Dec 31, 2024 | 9.37 Mn |
| Sep 30, 2024 | 17.92 Mn |
| Jun 30, 2024 | 22.15 Mn |
| Mar 31, 2024 | 21.24 Mn |
| Dec 31, 2023 | 23.68 Mn |
| Sep 30, 2023 | 27.20 Mn |
| Jun 30, 2023 | 21.62 Mn |
| Mar 31, 2023 | 21.29 Mn |
| Dec 31, 2022 | 15.24 Mn |
| Sep 30, 2022 | 16.97 Mn |
| Jun 30, 2022 | 14.80 Mn |
| Mar 31, 2022 | 14.46 Mn |
| Dec 31, 2021 | 12.62 Mn |
| Sep 30, 2021 | 10.71 Mn |
| Jun 30, 2021 | 12.02 Mn |
| Mar 31, 2021 | 7.45 Mn |
| Dec 31, 2020 | 5.19 Mn |
| Sep 30, 2020 | 5.83 Mn |
| Jun 30, 2020 | 1.68 Mn |
| Mar 31, 2020 | 592,000.00 |
| Dec 31, 2019 | 658,000.00 |
| Sep 30, 2019 | 1.03 Mn |